Table 2.
Patients' clinical and laboratory characteristics at initiation of antiretroviral therapy and latest clinical review
| Characteristics | Values for each patient | ||||
| Pt1 | Pt2 | Pt3 | Pt4 | Pt5 | |
| At ART initiation | |||||
| Haemoglobin (g/dl) | 12.7 | 12.6 | 11.0 | 12.1 | 12.8 |
| WHO clinical stage | 2 | 2 | 3 | 3 | 4§ |
| Stating ART regimen1 | AZT-3TC-NVP | AZT-3TC-NVP | AZT-3TC-NVP | AZT-3TC-NVP | AZT-3TC-EFZ |
| Weight (kilograms) | 55 | 48 | 59 | 35 | 51 |
| CD4 cell count (cells/µl) | 154* | 60* | 100* | 13* | 392 |
| Viral load (copies/ml) | 274,348 | 48,900 | 386,306 | 311,000 | 33,964 |
| At latest clinic review | |||||
| Time since ART start (months) |
84 | 30 | 48 | 6 | 66 |
| Current ART regimen1 | TDF-3TC-LPV/r | AZT-3TC-NVP | TDF-3TC-LPV/r | AZT-3TC-NVP | None |
| Weight (kilograms) | 51 | 44 | 67 | 42 | 54 |
| Percent weight gain | −7% | −8% | +14% | +20% | +6% |
| CD4 cell count (cells/µl) | 75 | 9 | 294 | 68 | 594 |
| Viral load (copies/ml) | 272,088 | 150,491 | 104 | 35,621 | 21,500 |
1
ART regimens: AZT-3TC-NVP - zidovudine, lamivudine, nevirapine, AZT-3TC-EFZ - zidovudine, lamivudine, efavirenz; TDF-3TC-LPV/r - tenofovir, lamivudine, ritonavir boosted lopinavir
Main ART eligibility criteria:
*
CD4 cell count less than 200 cells/µl
§
WHO clinical stage 4